276 related articles for article (PubMed ID: 29845708)
1. Oncogenic roles of enhancer of zeste homolog 1/2 in hematological malignancies.
Nakagawa M; Kitabayashi I
Cancer Sci; 2018 Aug; 109(8):2342-2348. PubMed ID: 29845708
[TBL] [Abstract][Full Text] [Related]
2. Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.
Sashida G; Iwama A
Int J Hematol; 2017 Jan; 105(1):23-30. PubMed ID: 27830540
[TBL] [Abstract][Full Text] [Related]
3. A Noncanonical Function of Polycomb Repressive Complexes Promotes Human Cytomegalovirus Lytic DNA Replication and Serves as a Novel Cellular Target for Antiviral Intervention.
Svrlanska A; Reichel A; Schilling EM; Scherer M; Stamminger T; Reuter N
J Virol; 2019 May; 93(9):. PubMed ID: 30814291
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.
Nakagawa M; Fujita S; Katsumoto T; Yamagata K; Ogawara Y; Hattori A; Kagiyama Y; Honma D; Araki K; Inoue T; Kato A; Inaki K; Wada C; Ono Y; Yamamoto M; Miura O; Nakashima Y; Kitabayashi I
Cancer Sci; 2019 Jan; 110(1):194-208. PubMed ID: 30343511
[TBL] [Abstract][Full Text] [Related]
5. Polycomb Repressive Complex 2 Proteins EZH1 and EZH2 Regulate Timing of Postnatal Hepatocyte Maturation and Fibrosis by Repressing Genes With Euchromatic Promoters in Mice.
Grindheim JM; Nicetto D; Donahue G; Zaret KS
Gastroenterology; 2019 May; 156(6):1834-1848. PubMed ID: 30689973
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic Impacts of Dysregulated Polycomb Repressive Complex Function in Hematological Malignancies.
Kaito S; Iwama A
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374737
[TBL] [Abstract][Full Text] [Related]
7. The role of EZH1 and EZH2 in development and cancer.
Lee SH; Li Y; Kim H; Eum S; Park K; Lee CH
BMB Rep; 2022 Dec; 55(12):595-601. PubMed ID: 36476271
[TBL] [Abstract][Full Text] [Related]
8. Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons.
Henriquez B; Bustos FJ; Aguilar R; Becerra A; Simon F; Montecino M; van Zundert B
Mol Cell Neurosci; 2013 Nov; 57():130-43. PubMed ID: 23932971
[TBL] [Abstract][Full Text] [Related]
9. EZH2: not EZHY (easy) to deal.
Deb G; Singh AK; Gupta S
Mol Cancer Res; 2014 May; 12(5):639-53. PubMed ID: 24526064
[TBL] [Abstract][Full Text] [Related]
10. Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner.
Mochizuki-Kashio M; Aoyama K; Sashida G; Oshima M; Tomioka T; Muto T; Wang C; Iwama A
Blood; 2015 Sep; 126(10):1172-83. PubMed ID: 26219303
[TBL] [Abstract][Full Text] [Related]
11. The competitive mechanism of EZH1 and EZH2 in promoting oral squamous cell carcinoma.
Chen J; Tang S; Zheng Q; Li J; Jiang H; Lu H; Liao G; Li K; Liang Y
Exp Cell Res; 2024 Mar; 436(1):113957. PubMed ID: 38309675
[TBL] [Abstract][Full Text] [Related]
12. microRNA-150 targets major epigenetic repressors and inhibits cell proliferation.
Selvam M; Bandi V; Ponne S; Ashok C; Baluchamy S
Exp Cell Res; 2022 Jun; 415(1):113110. PubMed ID: 35351403
[TBL] [Abstract][Full Text] [Related]
13. [Research Progress of Expression and Clinical Significant of EZH2 in Hematological Malignancies--Review].
Hu JY; Ji YR; Liu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):2097-2012. PubMed ID: 33283749
[TBL] [Abstract][Full Text] [Related]
14. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Honma D; Kanno O; Watanabe J; Kinoshita J; Hirasawa M; Nosaka E; Shiroishi M; Takizawa T; Yasumatsu I; Horiuchi T; Nakao A; Suzuki K; Yamasaki T; Nakajima K; Hayakawa M; Yamazaki T; Yadav AS; Adachi N
Cancer Sci; 2017 Oct; 108(10):2069-2078. PubMed ID: 28741798
[TBL] [Abstract][Full Text] [Related]
15. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
[TBL] [Abstract][Full Text] [Related]
16. Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader.
Yu X; Wang J; Gong W; Ma A; Shen Y; Zhang C; Liu X; Cai L; Liu J; Wang GG; Jin J
Oncogene; 2023 Mar; 42(13):994-1009. PubMed ID: 36747009
[TBL] [Abstract][Full Text] [Related]
17. The roles of EZH2 in cancer and its inhibitors.
Liu Y; Yang Q
Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
[TBL] [Abstract][Full Text] [Related]
18. Going beyond Polycomb: EZH2 functions in prostate cancer.
Park SH; Fong KW; Mong E; Martin MC; Schiltz GE; Yu J
Oncogene; 2021 Sep; 40(39):5788-5798. PubMed ID: 34349243
[TBL] [Abstract][Full Text] [Related]
19. Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.
Gall Trošelj K; Novak Kujundzic R; Ugarkovic D
Clin Epigenetics; 2016; 8():55. PubMed ID: 27239242
[TBL] [Abstract][Full Text] [Related]
20. Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
Yang X; Li F; Konze KD; Meslamani J; Ma A; Brown PJ; Zhou MM; Arrowsmith CH; Kaniskan HÜ; Vedadi M; Jin J
J Med Chem; 2016 Aug; 59(16):7617-33. PubMed ID: 27468126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
